Immunic, inc. announces closing of $45.0 million public offering

New york, july 19, 2021 /prnewswire/ -- immunic, inc. (the "company") (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $10.00 per share. the company received total proceeds from the offering, before deducting the underwriting discounts and other offering expenses, of $45.0 million.
IMUX Ratings Summary
IMUX Quant Ranking